Interferon Therapy
Collaboration Will Develop and Market Low-Dose Oral Interferon-(alpha) for Hepatitis C
Published in Hepatitis Weekly, May 29th, 2000
Amarillo Biosciences, Inc. (AMAR) and Biopharm Group International with corporate headquarters in Cairo, Egypt, and offices in Herndon and Reston, Virginia, jointly announced the execution of an agreement between the companies for the clinical co-development and marketing of Amarillo Biosciences' low dose orally administered interferon alpha (IFN (alpha)) in conjunction with an antiviral, for use in the treatment of hepatitis C.
Viral hepatitis is a worldwide health problem of enormous proportions and consequences. It is the most common cause of jaundice, chronic liver disease, cirrhosis, and hepatocellular carcinoma. It has been estimated by the World Health...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2000-05-29)
More Articles from Hepatitis Weekly
- Etiology
GB Virus-C/Hepatitis G Virus Defined as Lymphotropic by Researchers - Epidemiology (HBV)
Asian Countries Should Look to International Community for Vaccine Programs - Food Safety
Bacteriophage Assay Indicates Viral Contamination in Shellfish - Hepatocellular Carcinoma
Dendrite Cell Activity Decreases in Patients with Liver Cancer - Interferon Therapy (HCV)
Interferon Limits Iron Deposition and Hepatic Peroxidation - Organ Rejection
Hepatocyte Growth Factor Potentially Both Therapeutic and Dangerous - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
